Correction — September 3, 2026: An earlier version of this article stated that Generate Biomedicines shares reached an all-time high of $20.38 on Aug. 25, and attributed the decline that followed to the poster leak. Both were wrong. The $20.38 figure was the Aug. 25 closing price; the intraday high was $22.67. Shares rose 15.01% on Aug. 25, the day the posters appeared, and fell 20.80% on Aug. 26, when the company’s 180-day post-IPO lock-up expired and 103.14 million shares became eligible for sale. This article has been rewritten.

Generate Biomedicines said three draft conference posters on its AI-created inflammation asset GB-0895 were inadvertently made publicly available through the European Respiratory Society website on Aug. 25, nearly two weeks before the Sept. 7 embargo expired. The company disclosed the leak in an SEC filing after the materials, accepted for presentation at this year’s European Respiratory Society Congress in Spain, appeared online ahead of schedule.

Shares rose 15.01% on Aug. 25, the day the posters appeared, closing at $20.38 after an intraday high of $22.67. They fell 20.80% the following session to close at $16.14 on Aug. 26, the day the company’s 180-day post-IPO lock-up expired and 103.14 million shares held by insiders and early investors became eligible for sale. BioSpace reported that the ERS had not responded about why the data were shared before the embargo lifted, and Generate Biomedicines had not responded to a request for comment.

The Data

GB-0895, also known as golukibart, is an anti-TSLP monoclonal antibody engineered using generative artificial intelligence. One of the leaked posters covered already-shared design details for a pair of late-stage asthma trials, but the other two included new clinical findings.

One poster described an ongoing Phase 1 study in chronic obstructive pulmonary disease involving 40 patients. Generate Biomedicines said a single dose led to rapid and sustained reductions across four COPD biomarkers. In patients with elevated blood eosinophil count, the company said one dose showed broad and durable anti-inflammatory activity lasting at least six months. The placebo-controlled, ascending-dose study also showed a half-life of nearly 100 days.

The company said GB-0895 was well tolerated, with most treatment-emergent adverse events mild or moderate. Across all groups, six serious TEAEs were recorded among five patients, and Generate Biomedicines said none were above Grade 3 severity or related to the investigational treatment.

Another poster provided follow-up data from a Phase 1 asthma trial. Those results indicated that a lower single 300-mg dose showed broad anti-inflammatory activity for at least six months, which BioSpace said could support the company’s twice-yearly dosing plan.

Why The Leak Matters

The scientific takeaway is that Generate Biomedicines is trying to pair AI-enabled antibody design with a dosing profile that could matter commercially in chronic respiratory disease. The market’s first read on the data was positive, with shares gaining 15.01% on the day the posters surfaced. The decline that followed coincided with the lock-up expiry rather than with any new information about the programme, a reminder that share-price moves around a newly public company can reflect supply rather than science. Generate Biomedicines raised $400 million at the end of February, and as of June 30 it had $457.4 million in cash that it expects to last into the first half of 2028.